Lord Abbett & CO. LLC Boosts Stock Position in uniQure N.V. $QURE

Key Points

• Lord Abbett & CO. LLC increased its holdings in uniQure N.V. by 27.5% during the first quarter, now owning 400,785 shares valued at approximately $4.25 million.
• Several other institutional investors significantly raised their stakes in uniQure, with Invesco Ltd. boosting its holdings by 453.2% in the fourth quarter.
• uniQure reported a revenue of $5.26 million for the last quarter, exceeding analyst expectations, while the stock has a consensus rating of "Moderate Buy" with a target price of $37.45.

Lord Abbett & CO. LLC grew its stake in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 27.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 400,785 shares of the biotechnology company's stock after purchasing an additional 86,372 shares during the period. Lord Abbett & CO. LLC owned approximately 0.73% of uniQure worth $4,248,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Avoro Capital Advisors LLC purchased a new stake in uniQure in the fourth quarter worth $38,410,000. RTW Investments LP boosted its holdings in shares of uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after buying an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after buying an additional 794,459 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in shares of uniQure in the 4th quarter worth about $13,245,000. Finally, Integral Health Asset Management LLC increased its stake in shares of uniQure by 175.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock worth $19,426,000 after acquiring an additional 700,000 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Guggenheim reissued a "buy" rating and set a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research report on Wednesday, July 30th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Chardan Capital reduced their price target on uniQure from $38.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, July 29th. Finally, Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, uniQure currently has a consensus rating of "Buy" and a consensus price target of $37.45.

uniQure Stock Performance

Shares of QURE traded up $0.0630 during mid-day trading on Thursday, hitting $15.5430. 304,051 shares of the company traded hands, compared to its average volume of 1,372,933. The stock has a market cap of $852.84 million, a price-to-earnings ratio of -3.98 and a beta of 0.11. The stock has a 50-day moving average price of $14.56 and a two-hundred day moving average price of $13.64. uniQure N.V. has a 1 year low of $4.45 and a 1 year high of $19.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. Equities analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Buying and Selling

In other uniQure news, Director Rachelle Suzanne Jacques sold 2,112 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director owned 28,346 shares of the company's stock, valued at approximately $409,599.70. This represents a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Madhavan Balachandran sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director owned 37,697 shares in the company, valued at $544,721.65. This trade represents a 5.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock valued at $322,426 over the last ninety days. 4.79% of the stock is owned by insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.